SCHEMBL27635397

SCHEMBL27635397

O=Cc1c(C(F)(F)F)ccnc1OCCCCOCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.39
FAAH O00519 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
MGLL Q99685 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KCNA3 P22001 1/20 0.34
KCNA5 P22460 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5366905 0.75 AR (0.36) ARL3MBTL1NPC1MAPTRAB9A
SCHEMBL27656351 0.68 FAAH (0.39) FAAHL3MBTL1TDP1KCNA3KCNA5
SCHEMBL713499 0.68 TSHR (0.50) L3MBTL1TDP1SMN1; SMN2HRH4HRH3
SCHEMBL4288063 0.68 L3MBTL1 (0.40) ARL3MBTL1NPC1MAPTRAB9A
SCHEMBL2640223 0.67 TSHR (0.70) L3MBTL1TDP1KCNA3HRH4HRH3
SCHEMBL711369 0.67 L3MBTL1 (0.50) L3MBTL1TDP1SMN1; SMN2HRH4HRH3
SCHEMBL18585071 0.67 L3MBTL1 (0.50) L3MBTL1TDP1SMN1; SMN2HRH4HRH3
SCHEMBL6211503 0.67 L3MBTL1 (0.50) L3MBTL1TDP1SMN1; SMN2HRH4HRH3
SCHEMBL5561948 0.67 L3MBTL1 (0.50) L3MBTL1TDP1SMN1; SMN2HRH4HRH3
SCHEMBL1009942 0.67 L3MBTL1 (0.50) L3MBTL1TDP1SMN1; SMN2HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100422181-C [1,8] naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT CO (US) 2008-10-01 CN disclosed
CN-1839134-A [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT CO (US) 2006-09-27 CN disclosed